207 related articles for article (PubMed ID: 9447502)
1. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease.
Auchus AP; Bissey-Black C
J Neuropsychiatry Clin Neurosci; 1997; 9(4):591-3. PubMed ID: 9447502
[TBL] [Abstract][Full Text] [Related]
2. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
Devanand DP; Pelton GH; Cunqueiro K; Sackeim HA; Marder K
Int J Geriatr Psychiatry; 2011 Sep; 26(9):937-43. PubMed ID: 21845596
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial.
Verhey FR; Verkaaik M; Lousberg R;
Dement Geriatr Cogn Disord; 2006; 21(1):1-8. PubMed ID: 16244481
[TBL] [Abstract][Full Text] [Related]
4. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
Wernicke JF; Sayler ME; Koke SC; Pearson DK; Tollefson GD
Depress Anxiety; 1997; 6(1):31-9. PubMed ID: 9394873
[TBL] [Abstract][Full Text] [Related]
5. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment.
Allain H; Dautzenberg PH; Maurer K; Schuck S; Bonhomme D; Gérard D
Psychopharmacology (Berl); 2000 Mar; 148(4):361-6. PubMed ID: 10928308
[TBL] [Abstract][Full Text] [Related]
6. Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine.
Tollefson GD; Sayler ME
Depress Anxiety; 1996-1997; 4(6):294-311. PubMed ID: 9166658
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial.
Asadollahi S; Heidari K; Hatamabadi H; Vafaee R; Yunesian S; Azadbakht A; Mirmohseni L
Int Clin Psychopharmacol; 2015 May; 30(3):142-50. PubMed ID: 25500684
[TBL] [Abstract][Full Text] [Related]
8. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia.
Sultzer DL; Gray KF; Gunay I; Berisford MA; Mahler ME
Am J Geriatr Psychiatry; 1997; 5(1):60-9. PubMed ID: 9169246
[TBL] [Abstract][Full Text] [Related]
9. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
Andrezina R; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; McQuade RD
Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intranasal haloperidol in an acute Psychiatry Unit: a pilot study on schizophrenic patients with mild-modedate agitation.
Duñó Ambròs R; Oliva Morera JC; Iglesias-Lepine ML; Palao Vidal D; Monreal Ortiz JAMO; Labad Arias J
Actas Esp Psiquiatr; 2021 Sep; 49(5):205-209. PubMed ID: 34533203
[TBL] [Abstract][Full Text] [Related]
11. Urinary retention with venlafaxine-haloperidol combination.
Benazzi F
Pharmacopsychiatry; 1997 Jan; 30(1):27. PubMed ID: 9065967
[No Abstract] [Full Text] [Related]
12. Urinary retention with fluoxetine-haloperidol combination in a young patient.
Benazzi F
Can J Psychiatry; 1996 Nov; 41(9):606-7. PubMed ID: 8946091
[No Abstract] [Full Text] [Related]
13. Regression to the mean: implications for clinical trials of psychotropic agents in dementia.
Cummings JL; Tractenberg RE; Gamst A; Teri L; Masterman D; Thal LJ
Curr Alzheimer Res; 2004 Nov; 1(4):323-8. PubMed ID: 15975061
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.
Devanand DP; Marder K; Michaels KS; Sackeim HA; Bell K; Sullivan MA; Cooper TB; Pelton GH; Mayeux R
Am J Psychiatry; 1998 Nov; 155(11):1512-20. PubMed ID: 9812111
[TBL] [Abstract][Full Text] [Related]
15. Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease.
Risse SC; Lampe TH; Cubberley L
J Clin Psychiatry; 1987 May; 48(5):207-8. PubMed ID: 2883174
[TBL] [Abstract][Full Text] [Related]
16. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
Holmes C; Wilkinson D; Dean C; Clare C; El-Okl M; Hensford C; Moghul S
Int J Geriatr Psychiatry; 2007 Apr; 22(4):380-1. PubMed ID: 17380475
[No Abstract] [Full Text] [Related]
17. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease.
Olin JT; Fox LS; Pawluczyk S; Taggart NA; Schneider LS
Am J Geriatr Psychiatry; 2001; 9(4):400-5. PubMed ID: 11739066
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Suh GH; Greenspan AJ; Choi SK
Int J Geriatr Psychiatry; 2006 Jul; 21(7):654-60. PubMed ID: 16821257
[TBL] [Abstract][Full Text] [Related]
19. The use of haloperidol in the agitated, critically ill pediatric patient with burns.
Brown RL; Henke A; Greenhalgh DG; Warden GD
J Burn Care Rehabil; 1996; 17(1):34-8. PubMed ID: 8808357
[TBL] [Abstract][Full Text] [Related]
20. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
